glp-1 review article A new by Clifford J. Rosen, MD, and Julie R. Ingelfinger, MD, describes a new generation of treatment with receptor agonists for persons with obesity with or without diabetes or GLP-1 Drugs Show Potential Anti-Cancer

46 There is a relationship between HFpEF and obesity, with the latter considered not only a significant comorbidity but also a direct contributor to HFpEF

I've referred a friend and she is having a great experience too

Bonnet, who co-authored a major clinical advisory on nutrition and GLP-1 therapy, said the key to success with GLP-1s is pairing the drugs with lifestyle changes healthier food choices and more activity

Future of transdermal GLP-1 delivery Research on true pharmaceutical-grade transdermal GLP-1 delivery is underway: Microneedle array patches : Use tiny dissolvable needles to deliver medication just below the skin Enhanced transdermal systems : Employ special technologies to improve skin penetration Controlled-release formulations : Designed for sustained delivery over days or weeks Animal studies have shown promising results, with some experimental patches achieving blood levels comparable to those of injections